You are on page 1of 2

966 Federal Register / Vol. 72, No.

5 / Tuesday, January 9, 2007 / Notices

Interested parties may submit comments By Order of the Federal Maritime Parts Open to the Public
on agreements to the Secretary, Federal Commission.
1. Approval of the minutes of the
Maritime Commission, Washington, DC Bryant L. VanBrakle,
December 18, 2006 Board member
20573, within ten days of the date this Secretary.
meeting.
notice appears in the Federal Register. [FR Doc. E7–103 Filed 1–8–07; 8:45 am] 2. Thrift Savings Plan activity report
Copies of agreements are available BILLING CODE 6730–01–P by the Executive Director.
through the Commission’s Office of 3. Quarterly Reports.
Agreements (202–523–5793 or a. Investment Policy Review.
tradeanalysis@fmc.gov).
b. Vendor Financial Reports.
Agreement No.: 010051–038. FEDERAL RESERVE SYSTEM 4. Participant Survey Update.
Title: Mediterranean Space Charter
Agreement. Change in Bank Control Notices; Parts Closed to the Public
Parties: Hapag-Lloyd USA LLC; A.P. Acquisition of Shares of Bank or Bank
5. Personnel.
Moller-Maersk A/S; Mediterranean Holding Companies
6. Security.
Shipping Company, S.A.; Hapag-Lloyd The notificants listed below have CONTACT PERSON FOR MORE INFORMATION:
AG; and Zim Integrated Shipping applied under the Change in Bank Thomas J. Trabucco, Director, Office of
Services, Ltd. Control Act (12 U.S.C. 1817(j)) and External Affairs, (202) 942–1640.
Filing Party: Wayne R. Rohde, Esq.; § 225.41 of the Board’s Regulation Y (12 Dated: January 5, 2006.
Sher & Blackwell LLP; 1850 M Street, CFR 225.41) to acquire a bank or bank Thomas K. Emswiler,
NW.; Suite 900; Washington, DC 20036. holding company. The factors that are
Secretary to the Board, Federal Retirement
Synopsis: The amendment updates CP considered in acting on the notices are Thrift Investment Board.
Ships (USA) LLC’s corporate name to set forth in paragraph 7 of the Act (12
[FR Doc. 07–54 Filed 1–5–07; 3:10 pm]
Hapag-Lloyd USA LLC. U.S.C. 1817(j)(7)).
BILLING CODE 6760–01–P
Agreement No.: 011733–018. The notices are available for
Title: Common Ocean Carrier Platform immediate inspection at the Federal
Agreement. Reserve Bank indicated. The notices
Parties: A.P. Moller-Maersk A/S; CMA also will be available for inspection at DEPARTMENT OF HEALTH AND
CGM; Hamburg-Süd; Hapag-Lloyd AG; the office of the Board of Governors. HUMAN SERVICES
Mediterranean Shipping Company S.A.; Interested persons may express their
and United Arab Shipping Company views in writing to the Reserve Bank Office of the Secretary
(S.A.G.) as shareholder parties, and indicated for that notice or to the offices
Alianca Navegacao e Logistica Ltda.; of the Board of Governors. Comments Findings of Research Misconduct
Kawasaki Kisen Kaisha Ltd.; MISC must be received not later than January
AGENCY: Office of the Secretary, HHS.
Berhad; Mitsui O.S.K. lines Ltd.; 24, 2007.
A. Federal Reserve Bank of Kansas ACTION: Notice.
Nippon Yusen Kaisha; Safmarine
Container Lines N.V.; Senator Lines City (Donna J. Ward, Assistant Vice SUMMARY: Notice is hereby given that
GmbH; and Tasman Orient Line C.V. as President) 925 Grand Avenue, Kansas the Office of Research Integrity (ORI)
non-shareholder parties. City, Missouri 64198-0001: and the Assistant Secretary for Health
Filing Party: Wayne R. Rohde, Esq.; 1. Kris Ann Carson, Mulvane, Kansas; have taken final action in the following
Sher & Blackwell LLP; 1850 M Street, as co–trustee of the Frank L. Carson, III case:
NW.; Suite 900; Washington, DC 20036. Trust No. 1, to retain voting shares of Jong Hyuk Park, Ph.D., University of
Synopsis: The amendment deletes CP Mulvane Bankshares, Inc., and thereby Pittsburgh: Based on accumulated
Ships Limited; CP Ships (USA) LLC; indirectly retain voting shares of evidence including the University of
FESCO Ocean Management Ltd.; and Mulvane State Bank, both in Mulvane, Pittsburgh (UP) investigation committee
P&O Nedlloyd Limited as parties to the Kansas. report and additional analysis and
agreement and changes Hapag-Lloyd’s Board of Governors of the Federal Reserve information obtained by the Office of
name. System, January 4, 2007. Research Integrity (ORI) during its
Agreement No.: 201174. Robert deV. Frierson, oversight review, the U.S. Public Health
Title: Port of Kalama/ConAgra Foods, Deputy Secretary of the Board. Service (PHS) found that Jong Hyuk
Inc./Kalama Export Company LLC/ [FR Doc. E7–83 Filed 1–8–07; 8:45 am] Park, Ph.D., former postdoctoral fellow,
Kalama Grain Terminal, Inc. Agreement. BILLING CODE 6210–01–S
Pittsburgh Development Center of the
Magee-Womens Research Institute, UP,
Parties: Port of Kalama; ConAgra
engaged in research misconduct in
Foods, Inc.; Kalama Export Company
research funded by National Center for
LLC; and Kalama Grain Terminal, Inc.
FEDERAL RETIREMENT THRIFT Research Resources (NCRR), National
Filing Party: Dennis A. Ostgard, Esq.; Institutes of Health (NIH), grant R24
Schwabe, Williamson & Wyatt; 1420 5th INVESTMENT BOARD
RR13632 and National Institute of Child
Avenue; Suite 3010; Seattle, WA 98101. Health and Human Development
Sunshine Act Meeting Notice
Synopsis: The agreement would (NICHD), NIH, grant P01 HD047675.
provide for termination of the Port of TIME AND DATE: 9 a.m. (EST); January 16, Specifically, Dr. Park:
Kalama’s tariff applicable to terminal 2007. (1) Intentionally and knowingly
facilities owned and/or operated by the falsified various versions of two figures
ycherry on PROD1PC63 with NOTICES

other parties and payment to the Port of PLACE: 4th Floor Conference Room,
1250 H Street, NW., Washington, DC. in a manuscript entitled ‘‘Rhesus
Kalama in lieu of dockage to be Embryonic Stem Cells Established by
calculated and determined from time to STATUS: Parts will be open to the public Nuclear Transfer: Tetraploid ESCs Differ
time. and parts closed to the public. from Fertilized Ones’’ that was being
Dated: January 4, 2007. MATTERS TO BE CONSIDERED: prepared for submission to Nature;

VerDate Aug<31>2005 13:55 Jan 08, 2007 Jkt 211001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\09JAN1.SGM 09JAN1
Federal Register / Vol. 72, No. 5 / Tuesday, January 9, 2007 / Notices 967

(2) Repeatedly misrepresented to the DATES: The public meeting will be held FDA is seeking comments on this
UP investigative panel the accuracy of on February 8, 2007, from 8 a.m. to 5 draft guidance and has extended the
one of the figures; p.m. Online registration is available comment period to March 5, 2007 (71
(3) Presented the false figures as true until 5 p.m. on February 5, 2007; FR 68822). FDA is announcing in this
to members of the laboratory; and however, if space permits onsite notice a public meeting on this draft
(4) Falsified the record of revisions of registration will be permitted on guidance.
the figures by deleting all prior versions February 8, 2007 (see the Registration
II. Agenda
from the laboratory server. section of this notice for details).
ORI has implemented the following ADDRESSES: The public meeting will be FDA will start the meeting with a
administrative actions for a period of held at the Grand Ballroom of the Hilton brief presentation on the draft guidance
three (3) years, beginning on November Washington DC/Gaithersburg Hotel entitled ‘‘Draft Guidance for Industry,
29, 2006: located at 620 Perry Pkwy., Clinical Laboratories, and FDA Staff on
(1) Dr. Park is debarred from any Gaithersburg, MD 20877. Additional In Vitro Diagnostic Multivariate Index
contracting or subcontracting with any information about and directions to the Assays.’’ The purpose of this meeting is
agency of the United States Government facility are available by calling the hotel to obtain public input on this guidance.
and from eligibility or involvement in at 1–301–977–8900 or on the Internet at: Hence, presentations by the public will
nonprocurement programs of the United http://www.hilton.com (under Find a make-up the remainder of the agenda.
States Government as defined in the Hotel, type in Gaithersburg, MD under Interested persons who would like to
debarment regulations at 45 CFR Part city and State). (FDA has verified the make a presentation during the meeting
76; and Web site address, but FDA is not will be given 10 minutes to do so if they
(2) Dr. Park is prohibited from serving responsible for any subsequent changes submit their request (electronic or
in any advisory capacity to PHS, to the Web site after this document written) and a copy of the material to be
including but not limited to service on publishes in the Federal Register.) presented by February 1, 2007, to the
any PHS advisory committee, board, The comment period on this draft contact person, Sousan Altaie, at the
and/or peer review committee, or as a guidance closes on March 5, 2007. address or the email above and to the
consultant. Submit written comments to the docket for this draft guidance.
FOR FURTHER INFORMATION CONTACT: Division of Dockets Management (HFA– Depending upon the number of
Director, Division of Investigative 305), Food and Drug Administration, presenters submitting requests to
Oversight, Office of Research Integrity, 5630 Fishers Lane, rm. 1061, Rockville, present, the allotted time may be
1101 Wootton Parkway, Suite 750, MD 20852. Submit electronic comments expanded or shortened to provide
Rockville, MD 20852, (240) 453–8800. on the draft guidance to http:// appropriate representation by all
www.fda.gov/dockets/ecomments. interested parties. Presentations and
Chris B. Pascal, Identify comments with the docket comments are to be identified with the
Director, Office of Research Integrity. number found in brackets in the docket number found in brackets in the
[FR Doc. E7–42 Filed 1–8–07; 8:45 am] heading of this document. heading of this document.
BILLING CODE 4150–31–P FOR FURTHER INFORMATION CONTACT:
This public meeting agenda will be
Sousan Altaie, Center for Devices and available on the Internet on February 7,
Radiological Health (HFZ–440), Food 2007, at http://www.fda.gov/cdrh/oivd/
DEPARTMENT OF HEALTH AND and Drug Administration, 2098 Gaither meetings/020807agenda.html.
HUMAN SERVICES Rd., Rockville, MD 20850, 240–276– III. Registration
0450, ext. 106, e-mail: Those interested in attending may
Food and Drug Administration
Sousan.Altaie@fda.hhs.gov. register online at http://
[Docket No. 2006D–0347]
SUPPLEMENTARY INFORMATION: www.accessdata.fda.gov/scripts/cdrh/
In Vitro Diagnostic Multivariate Index I. Background cfdocs/cfSUD/oivd_meeting.cfm. There
Assays; Public Meeting is no registration fee to attend the
FDA announced the availability of a meeting. Please submit registration early
AGENCY: Food and Drug Administration, draft guidance entitled ‘‘Draft Guidance in order to reserve a space, as space is
HHS. for Industry, Clinical Laboratories, and limited. You may register online until
ACTION: Notice of public meeting. FDA Staff on In Vitro Diagnostic February 5, 2007; however, onsite
Multivariate Index Assays,’’ on registration will be permitted if space
SUMMARY: The Food and Drug September 7, 2006 (71 FR 52800). This remains. If you require special
Administration (FDA) is announcing a draft guidance addresses the definition accommodations due to a disability,
public meeting on In Vitro Diagnostic and regulatory status of a class of in please contact the Hilton Washington
Multivariate Index Assays. The meeting vitro diagnostic devices referred to as In DC/Gaithersburg Hotel directly at 1–
is intended to provide a public forum Vitro Diagnostic Multivariate Index 301–977–8900, at least 7 days in
during which FDA will hear Assays (IVDMIAs). The draft guidance advance.
presentations and comments from also addresses premarket and Persons without Internet access may
interested stakeholders regarding the postmarket requirements with respect to call Sousan Altaie at 240–276–0450 ext.
draft guidance entitled ‘‘Draft Guidance IVDMIAs. An IVDMIA employs clinical 106, by February 5, 2007, to register for
for Industry, Clinical Laboratories, and data, which may be derived in part from onsite meeting attendance.
FDA Staff on In Vitro Diagnostic one or more in vitro assays, and an
Multivariate Index Assays.’’ This draft algorithm to integrate the variables, and IV. Request for Input and Materials
guidance is intended to provide reports a result that cannot be FDA is interested in receiving input
ycherry on PROD1PC63 with NOTICES

clarification on FDA’s approach to interpreted by the well-trained health from stakeholders on the draft guidance.
regulation of in vitro diagnostic care practitioner using prior knowledge Send suggestions or recommendations
multivariate index assays. FDA is of medicine without information from to the Division of Dockets Management
seeking comments on this draft the test developer regarding its clinical (see ADDRESSES). FDA will place an
guidance. performance and effectiveness. additional copy of any material it

VerDate Aug<31>2005 13:55 Jan 08, 2007 Jkt 211001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\09JAN1.SGM 09JAN1